PDA vs Thymosin Alpha-1
Both PDA and Thymosin Alpha-1 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
PDA
Evidence C+Pentadeca Arginate (PDA)
A 15-amino-acid arginate analog developed as a more stable, sometimes more bioavailable alternative to BPC-157. Limited published research; popular among compounding pharmacies in 2025–2026.
View full PDA profile →Thymosin Alpha-1
Evidence AThymosin Alpha-1 (Tα1)
A 28-amino-acid thymic peptide that matures and modulates T-cells. Used internationally as an adjunct in hepatitis, sepsis, and immune-compromised cancer care.
View full Thymosin Alpha-1 profile →Side-by-Side
| Attribute | PDA | Thymosin Alpha-1 |
|---|---|---|
| Evidence Grade | C+ | A |
| FDA Status | Not FDA-approved — newer compounded analog of BPC-157 | Approved in 35+ countries for hepatitis B/C, immune support; not FDA-approved in US (orphan-drug designations) |
| Typical Dose | 200–500 mcg daily (subcutaneous) | 1.6 mg twice weekly (subcutaneous) |
| Clinics Indexed | 41 | 192 |
| Categories | recovery, anti-inflammatory | immune, anti-inflammatory |
Key reported benefits — PDA
- ✓Tissue repair
- ✓Anti-inflammation
- ✓Potentially better stability than BPC-157
Key reported benefits — Thymosin Alpha-1
- ✓T-cell maturation
- ✓Antiviral immunity
- ✓Tumor immune support
- ✓Sepsis adjunct
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.